1
|
Cargou M, Elsermans V, Wojciechowski E, Tenchon O, Visentin J. Characterization of the novel HLA-DRB1*04:04:20 allele by sequencing-based typing. HLA 2024; 103:e15434. [PMID: 38451010 DOI: 10.1111/tan.15434] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2024] [Accepted: 02/27/2024] [Indexed: 03/08/2024]
Abstract
HLA-DRB1*04:04:20 differs from HLA-DRB1*04:04:01:04 by one nucleotide substitution in codon 135 in exon 3.
Collapse
Affiliation(s)
- Marine Cargou
- Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, CHU de Bordeaux, Bordeaux, France
| | | | - Elodie Wojciechowski
- Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, CHU de Bordeaux, Bordeaux, France
| | - Oceane Tenchon
- Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, CHU de Bordeaux, Bordeaux, France
- Bordeaux University, CNRS, INSERM, ImmunoConcEpt, UMR 5164, ERL 1303, Bordeaux, France
| | - Jonathan Visentin
- Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, CHU de Bordeaux, Bordeaux, France
- Bordeaux University, CNRS, INSERM, ImmunoConcEpt, UMR 5164, ERL 1303, Bordeaux, France
| |
Collapse
|
2
|
Cargou M, Andreani M, Troiano M, Guidicelli G, Visentin J. Characterization of the novel HLA-DQA1*01:03:11 allele by sequencing-based typing. HLA 2024; 103:e15433. [PMID: 38450901 DOI: 10.1111/tan.15433] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2024] [Accepted: 02/27/2024] [Indexed: 03/08/2024]
Abstract
HLA-DQA1*01:03:11 differs from HLA-DQA1*01:03:01:02 by one nucleotide substitution in codon 59 in exon 2.
Collapse
Affiliation(s)
- Marine Cargou
- Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, CHU de Bordeaux, Bordeaux, France
| | - Marco Andreani
- Laboratorio d'Immunogenetica dei Trapianti, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy
| | - Maria Troiano
- Laboratorio d'Immunogenetica dei Trapianti, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy
| | - Gwendaline Guidicelli
- Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, CHU de Bordeaux, Bordeaux, France
| | - Jonathan Visentin
- Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, CHU de Bordeaux, Bordeaux, France
- CNRS, INSERM, ImmunoConcEpt, UMR 5164, ERL 1303, Bordeaux University, Bordeaux, France
| |
Collapse
|
3
|
Viallard JF, Lescure M, Oksenhendler E, Blanco P, Visentin J, Parrens M. STAT expression and TFH1 cells in CVID granulomatosis and sarcoidosis: immunological and histopathological comparisons. Virchows Arch 2024; 484:481-490. [PMID: 37924346 DOI: 10.1007/s00428-023-03684-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2023] [Revised: 10/10/2023] [Accepted: 10/22/2023] [Indexed: 11/06/2023]
Abstract
Granulomatous disease is a serious complication of common variable immunodeficiency (CVID-GD) that occurs in 8-22% of these patients and can mimic sarcoidosis, with which it shares certain clinical, biological, and radiological features. However, few studies to date have compared the two pathologies immunologically and histologically. Therefore, we analyzed the immunological-histological findings for different tissue samples from ten patients with CVID-GD and compared them to those of biopsy-proven sarcoidosis. Specifically, we wanted to know whether or not the signaling abnormalities observed in sarcoidosis granulomas are also present in CVID-GD. Morphological differences were found between CVID-GD histology and classical sarcoidosis: mainly, the former's notable lymphoid hyperplasia associated with granulomas not observed in the latter. All CVID-GD involved organs contained several follicular helper-T (TFH) cells within the granulomatosis, while those cells were inconstantly and more weakly expressed in sarcoidosis. Moreover, CVID and sarcoidosis granulomas expressed the phosphorylated-signal transducer and activator of transcription (pSTAT)1 and pSTAT3 factors, regardless of the organ studied and without any significant difference between entities. Our results suggest that the macrophage-activation mechanism in CVID resembles that of sarcoidosis, thereby suggesting that Janus kinase (JAK)-STAT-pathway blockade might be useful in currently difficult-to-treat CVID-GD.
Collapse
Affiliation(s)
- Jean-François Viallard
- Internal Medicine Department, Hôpital Haut-Lévêque, Bordeaux University Hospital, Avenue de Magellan, 33604, Pessac, France.
| | - Maëlig Lescure
- Internal Medicine Department, Hôpital Haut-Lévêque, Bordeaux University Hospital, Avenue de Magellan, 33604, Pessac, France
| | - Eric Oksenhendler
- Clinical Immunology Department, Saint-Louis Paris Diderot University Hospital, Paris, France
| | - Patrick Blanco
- Centre Hospitalier Universitaire de Bordeaux, Service d'Immunologie Et Immunogénétique FHU ACRONIM, Hôpital Pellegrin, Place Amélie-Raba-Léon, Bordeaux, France
| | - Jonathan Visentin
- Centre Hospitalier Universitaire de Bordeaux, Service d'Immunologie Et Immunogénétique FHU ACRONIM, Hôpital Pellegrin, Place Amélie-Raba-Léon, Bordeaux, France
| | - Marie Parrens
- Pathology Department, Hôpital du Haut-Lévêque, Bordeaux University Hospital, Avenue de Magellan, Pessac, France
| |
Collapse
|
4
|
Bracken SJ, Suthers AN, DiCioccio RA, Su H, Anand S, Poe JC, Jia W, Visentin J, Basher F, Jordan CZ, McManigle WC, Li Z, Hakim FT, Pavletic SZ, Bhuiya NS, Ho VT, Horwitz ME, Chao NJ, Sarantopoulos S. Heightened TLR7 signaling primes BCR-activated B cells in chronic graft-versus-host disease for effector functions. Blood Adv 2024; 8:667-680. [PMID: 38113462 PMCID: PMC10839617 DOI: 10.1182/bloodadvances.2023010362] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2023] [Revised: 11/02/2023] [Accepted: 11/20/2023] [Indexed: 12/21/2023] Open
Abstract
ABSTRACT Chronic graft-versus-host disease (cGVHD) is a debilitating, autoimmune-like syndrome that can occur after allogeneic hematopoietic stem cell transplantation. Constitutively activated B cells contribute to ongoing alloreactivity and autoreactivity in patients with cGVHD. Excessive tissue damage that occurs after transplantation exposes B cells to nucleic acids in the extracellular environment. Recognition of endogenous nucleic acids within B cells can promote pathogenic B-cell activation. Therefore, we hypothesized that cGVHD B cells aberrantly signal through RNA and DNA sensors such as Toll-like receptor 7 (TLR7) and TLR9. We found that B cells from patients and mice with cGVHD had higher expression of TLR7 than non-cGVHD B cells. Using ex vivo assays, we found that B cells from patients with cGVHD also demonstrated increased interleukin-6 production after TLR7 stimulation with R848. Low-dose B-cell receptor (BCR) stimulation augmented B-cell responses to TLR7 activation. TLR7 hyperresponsiveness in cGVHD B cells correlated with increased expression and activation of the downstream transcription factor interferon regulatory factor 5. Because RNA-containing immune complexes can activate B cells through TLR7, we used a protein microarray to identify RNA-containing antigen targets of potential pathological relevance in cGVHD. We found that many of the unique targets of active cGVHD immunoglobulin G (IgG) were nucleic acid-binding proteins. This unbiased assay identified the autoantigen and known cGVHD target Ro-52, and we found that RNA was required for IgG binding to Ro-52. Herein, we find that BCR-activated B cells have aberrant TLR7 signaling responses that promote potential effector responses in cGVHD.
Collapse
Affiliation(s)
- Sonali J. Bracken
- Division of Rheumatology and Immunology, Department of Medicine, Duke University Medical Center, Durham, NC
| | - Amy N. Suthers
- Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University Medical Center, Durham, NC
| | - Rachel A. DiCioccio
- Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University Medical Center, Durham, NC
| | - Hsuan Su
- Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University Medical Center, Durham, NC
| | - Sarah Anand
- Division of Hematology and Medical Oncology, Department of Medicine, University of Michigan, Ann Arbor, MI
| | - Jonathan C. Poe
- Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University Medical Center, Durham, NC
| | - Wei Jia
- Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University Medical Center, Durham, NC
| | - Jonathan Visentin
- Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University Medical Center, Durham, NC
- Department of Immunology and Immunogenetics, Bordeaux University Hospital, Bordeaux, France
- UMR CNRS 5164 ImmunoConcEpT, Bordeaux University, Bordeaux, France
| | - Fahmin Basher
- Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University Medical Center, Durham, NC
| | - Collin Z. Jordan
- Division of Nephrology, Department of Medicine, Duke University Medical Center, Durham NC
| | - William C. McManigle
- Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, Duke University Medical Center, Durham NC
| | - Zhiguo Li
- Department of Biostatistics and Bioinformatics, Duke University Medical Center, Durham NC
- Duke Cancer Institute, Duke University Medical Center, Durham NC
| | - Frances T. Hakim
- Experimental Transplantation and Immunology Branch, National Cancer Institute, Bethesda, MD
| | - Steven Z. Pavletic
- Experimental Transplantation and Immunology Branch, National Cancer Institute, Bethesda, MD
| | - Nazmim S. Bhuiya
- Experimental Transplantation and Immunology Branch, National Cancer Institute, Bethesda, MD
| | - Vincent T. Ho
- Division of Hematologic Malignancies and Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
| | - Mitchell E. Horwitz
- Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University Medical Center, Durham, NC
- Duke Cancer Institute, Duke University Medical Center, Durham NC
| | - Nelson J. Chao
- Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University Medical Center, Durham, NC
- Duke Cancer Institute, Duke University Medical Center, Durham NC
- Department of Integrated Immunobiology, Duke University School of Medicine, Durham, NC
| | - Stefanie Sarantopoulos
- Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University Medical Center, Durham, NC
- Duke Cancer Institute, Duke University Medical Center, Durham NC
- Department of Integrated Immunobiology, Duke University School of Medicine, Durham, NC
| |
Collapse
|
5
|
Cargou M, Elsermans V, Top I, Duclaut M, Visentin J. Characterization of the novel HLA-B*51:394Q allele by sequencing-based typing. HLA 2024; 103:e15404. [PMID: 38372598 DOI: 10.1111/tan.15404] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2024] [Revised: 02/02/2024] [Accepted: 02/06/2024] [Indexed: 02/20/2024]
Abstract
HLA-B*51:394Q differs from HLA-B*51:01:01:05 by one nucleotide substitution in codon 339 in exon 7.
Collapse
Affiliation(s)
- Marine Cargou
- CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, Bordeaux, France
| | | | - Isabelle Top
- CHU de Lille, Institut d'Immunologie-HLA, Lille, France
| | - Marion Duclaut
- CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, Bordeaux, France
- CNRS, ImmunoConcEpT, UMR 5164, University of Bordeaux, Bordeaux, France
| | - Jonathan Visentin
- CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, Bordeaux, France
- CNRS, ImmunoConcEpT, UMR 5164, University of Bordeaux, Bordeaux, France
| |
Collapse
|
6
|
Cargou M, Elsermans V, Top I, Tenchon O, Visentin J. Characterization of the novel HLA-B*14:121 allele by sequencing-based typing. HLA 2024; 103:e15396. [PMID: 38358082 DOI: 10.1111/tan.15396] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2024] [Accepted: 02/02/2024] [Indexed: 02/16/2024]
Abstract
HLA-B*14:121 differs from HLA-B*14:01:01:01 by one nucleotide substitution in codon 319 in exon 6.
Collapse
Affiliation(s)
- Marine Cargou
- CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, Bordeaux, France
| | - Vincent Elsermans
- CHU de Lille, Institut d'Immunologie-HLA, Bd du Professeur Jules Leclercq, Lille, France
| | - Isabelle Top
- CHU de Lille, Institut d'Immunologie-HLA, Bd du Professeur Jules Leclercq, Lille, France
| | - Océane Tenchon
- CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, Bordeaux, France
- Bordeaux University, CNRS, INSERM, ImmunoConcEpt, UMR 5164, ERL 1303, Bordeaux, France
| | - Jonathan Visentin
- CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, Bordeaux, France
- Bordeaux University, CNRS, INSERM, ImmunoConcEpt, UMR 5164, ERL 1303, Bordeaux, France
| |
Collapse
|
7
|
Cargou M, Elsermans V, Top I, Duclaut M, Visentin J. Characterization of the novel HLA-C*01:263 allele by sequencing-based typing. HLA 2024; 103:e15392. [PMID: 38372574 DOI: 10.1111/tan.15392] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2024] [Accepted: 02/02/2024] [Indexed: 02/20/2024]
Abstract
HLA-C*01:263 differs from HLA-C*01:02:01:01 by one nucleotide substitution in codon 98 in exon 3.
Collapse
Affiliation(s)
- Marine Cargou
- CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, Bordeaux, France
| | - Vincent Elsermans
- CHU de Lille, Institut d'Immunologie-HLA, Bd du Professeur Jules Leclercq, Lille, France
| | - Isabelle Top
- CHU de Lille, Institut d'Immunologie-HLA, Bd du Professeur Jules Leclercq, Lille, France
| | - Marion Duclaut
- CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, Bordeaux, France
- Bordeaux University, CNRS, INSERM, ImmunoConcEpt, UMR 5164, ERL 1303, Bordeaux, France
| | - Jonathan Visentin
- CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, Bordeaux, France
- Bordeaux University, CNRS, INSERM, ImmunoConcEpt, UMR 5164, ERL 1303, Bordeaux, France
| |
Collapse
|
8
|
Cargou M, Elsermans V, Top I, Duclaut M, Visentin J. Characterization of the novel HLA-C*05:286 allele by sequencing-based typing. HLA 2024; 103:e15393. [PMID: 38372565 DOI: 10.1111/tan.15393] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2024] [Accepted: 02/02/2024] [Indexed: 02/20/2024]
Abstract
HLA-C*05:286 differs from HLA-C*05:01:01:02 by one nucleotide substitution in codon 283 in exon 5.
Collapse
Affiliation(s)
- Marine Cargou
- CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, Bordeaux, France
| | - Vincent Elsermans
- CHU de Lille, Institut d'Immunologie-HLA, Bd du Professeur Jules Leclercq, Lille, France
| | - Isabelle Top
- CHU de Lille, Institut d'Immunologie-HLA, Bd du Professeur Jules Leclercq, Lille, France
| | - Marion Duclaut
- CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, Bordeaux, France
- CNRS, INSERM, ImmunoConcEpt, Bordeaux University, UMR 5164, Bordeaux, France
| | - Jonathan Visentin
- CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, Bordeaux, France
- CHU de Lille, Institut d'Immunologie-HLA, Bd du Professeur Jules Leclercq, Lille, France
| |
Collapse
|
9
|
Elsermans V, Visentin J, Cargou M, Top I, Labalette M. Characterization of the novel HLA-C*06:176:02 allele by sequencing-based typing. HLA 2024; 103:e15253. [PMID: 37827836 DOI: 10.1111/tan.15253] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2023] [Accepted: 09/28/2023] [Indexed: 10/14/2023]
Abstract
HLA-C*06:176:02 differs from HLA-C*06:176:01 by two nucleotide substitutions in codons 236 and 237 in exon 4.
Collapse
Affiliation(s)
| | - Jonathan Visentin
- Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, CHU de Bordeaux, Bordeaux, France
- Université de Bordeaux, UMR CNRS 5164 Immunoconcept, Bordeaux, France
| | - Marine Cargou
- Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, CHU de Bordeaux, Bordeaux, France
| | - Isabelle Top
- CHU de Lille, Institut d'Immunologie-HLA, Lille, France
| | - Myriam Labalette
- CHU de Lille, Institut d'Immunologie-HLA, Lille, France
- Université de Lille, Inserm U1286 INFINITE, Lille, France
| |
Collapse
|
10
|
Blandin L, Visentin J, Guidicelli G, Lemal R, Rouzaire P. Characterization of the novel HLA-DRB3*02:194 allele by sequencing-based typing. HLA 2024; 103:e15353. [PMID: 38273423 DOI: 10.1111/tan.15353] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/09/2024] [Accepted: 01/10/2024] [Indexed: 01/27/2024]
Abstract
HLA-DRB3*02:194 differs from HLA-DRB3*02:02:01:02 by one nucleotide substitution in codon 78 in exon 2.
Collapse
Affiliation(s)
- Lucie Blandin
- Histocompatibility and Immunogenetics Laboratory, Clermont-Ferrand University Hospital, Clermont-Ferrand, France
| | - Jonathan Visentin
- Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, CHU de Bordeaux, Bordeaux, France
- University Bordeaux, CNRS, ImmunoConcEpT, UMR 5164, Bordeaux, France
| | - Gwendaline Guidicelli
- Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, CHU de Bordeaux, Bordeaux, France
| | - Richard Lemal
- Histocompatibility and Immunogenetics Laboratory, Clermont-Ferrand University Hospital, Clermont-Ferrand, France
- Clermont-Auvergne University, EA7453 CHELTER, Clermont-Ferrand, France
| | - Paul Rouzaire
- Histocompatibility and Immunogenetics Laboratory, Clermont-Ferrand University Hospital, Clermont-Ferrand, France
- Clermont-Auvergne University, EA7453 CHELTER, Clermont-Ferrand, France
| |
Collapse
|
11
|
Bakis H, Bouthemy C, Corcuff JB, Lauro C, Guidicelli G, Cargou M, Guibet C, Taton B, Merville P, Couzi L, Moreau K, Visentin J. 25-hydroxyvitamin D sufficiency is associated with lower de novo anti-HLA donor specific antibody and better kidney transplant outcomes. HLA 2024; 103:e15187. [PMID: 37604171 DOI: 10.1111/tan.15187] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2023] [Revised: 06/30/2023] [Accepted: 07/28/2023] [Indexed: 08/23/2023]
Abstract
T-cell mediated rejection (TCMR), de novo anti-HLA donor-specific antibodies (dnDSAs) and ensuing antibody-mediated rejection (ABMR) reduce kidney transplantation (KT) survival. The immunomodulatory effects of 25-hydroxyvitamin D [25(OH)D] could be beneficial for KT outcomes. We aimed to evaluating the association between 25(OH)D levels, the development of dnDSAs, clinical TCMR and ABMR, and graft survival. This single center retrospective study included 253 KT recipients (KTRs) transplanted without preformed DSA between 2010 and 2013. We measured 25(OH)D in successive serum samples: at KT (M0) and M12 for the entire cohort, and additionally at M24 and/or M36 when sera were available. We assessed graft outcomes up to 5 years post-KT. The proportion of KTRs having sufficient 25(OH)D at KT (M0) was high (81.4%) and then dropped at M12 (71.1%). KTRs with sufficient 25(OH)D at M0 experienced less clinical TCMR (HR, 0.41; 95% CI, 0.19-0.88 in multivariate analysis). A sufficient 25(OH)D at M12 was independently associated with a longer dnDSA-free survival (HR, 0.34; 95% CI, 0.17-0.69). There was no association between 25(OH)D and clinical AMBR. Studying the KTRs with 25(OH)D measurements at M12, M24 and M36 (n = 203), we showed that 25(OH)D sufficiency over the 3 first-years post-KT was associated with a longer graft survival in multivariate analyses (HR, 0.39; 95% CI, 0.22-0.70). To our knowledge, this study is the first showing an association between 25(OH)D sufficiency post-KT and dnDSA occurrence in KTRs. Moreover, we reinforce previously published data showing an association between 25(OH)D, TCMR and graft survival in KT.
Collapse
Affiliation(s)
- Hugo Bakis
- CHU de Bordeaux, Service de Néphrologie, Transplantation, Dialyse et Aphérèses, Bordeaux, France
| | - Charlène Bouthemy
- CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, Bordeaux, France
- Univ. Bordeaux, CNRS, INSERM, ImmunoConcEpT, UMR 5164, Bordeaux, France
| | - Jean-Benoît Corcuff
- CHU de Bordeaux, Laboratoire d'Hormonologie et de Médecine Nucléaire, Hôpital Pellegrin, Bordeaux, France
- Univ. Bordeaux, Nutrition and Integrated Neurobiology, UMR INRA 1286, Bordeaux, France
| | - Cindy Lauro
- CHU de Bordeaux, Laboratoire d'Hormonologie et de Médecine Nucléaire, Hôpital Pellegrin, Bordeaux, France
| | - Gwendaline Guidicelli
- CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, Bordeaux, France
| | - Marine Cargou
- CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, Bordeaux, France
| | - Claire Guibet
- CHU de Bordeaux, Laboratoire d'Hormonologie et de Médecine Nucléaire, Hôpital Pellegrin, Bordeaux, France
| | - Benjamin Taton
- CHU de Bordeaux, Service de Néphrologie, Transplantation, Dialyse et Aphérèses, Bordeaux, France
- Univ. Bordeaux, Univ. Bordeaux, Inria Bordeaux Sud-Ouest, Bordeaux, France
| | - Pierre Merville
- CHU de Bordeaux, Service de Néphrologie, Transplantation, Dialyse et Aphérèses, Bordeaux, France
- Univ. Bordeaux, CNRS, INSERM, ImmunoConcEpT, UMR 5164, Bordeaux, France
| | - Lionel Couzi
- CHU de Bordeaux, Service de Néphrologie, Transplantation, Dialyse et Aphérèses, Bordeaux, France
- Univ. Bordeaux, CNRS, INSERM, ImmunoConcEpT, UMR 5164, Bordeaux, France
| | - Karine Moreau
- CHU de Bordeaux, Service de Néphrologie, Transplantation, Dialyse et Aphérèses, Bordeaux, France
| | - Jonathan Visentin
- CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, Bordeaux, France
- Univ. Bordeaux, CNRS, INSERM, ImmunoConcEpT, UMR 5164, Bordeaux, France
| |
Collapse
|
12
|
Blandin L, Visentin J, Duclaut M, Lemal R, Rouzaire P. Characterization of the novel HLA-C*16:98:02 allele by sequencing-based typing. HLA 2024; 103:e15285. [PMID: 37942829 DOI: 10.1111/tan.15285] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/18/2023] [Revised: 10/23/2023] [Accepted: 10/27/2023] [Indexed: 11/10/2023]
Abstract
HLA-C*16:98:02 differs from HLA-C*16:98:01 by one nucleotide substitution in codon 132 in exon 3.
Collapse
Affiliation(s)
- Lucie Blandin
- Histocompatibility and Immunogenetics laboratory, Clermont-Ferrand University Hospital, Clermont-Ferrand, France
| | - Jonathan Visentin
- CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, Bordeaux, France
- Univ. Bordeaux, CNRS, ImmunoConcEpT, UMR 5164, 146 rue Léo Saignat, Bordeaux, France
| | - Marion Duclaut
- CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, Bordeaux, France
| | - Richard Lemal
- Histocompatibility and Immunogenetics laboratory, Clermont-Ferrand University Hospital, Clermont-Ferrand, France
- EA7453 CHELTER, Clermont-Auvergne University, Clermont-Ferrand, France
| | - Paul Rouzaire
- Histocompatibility and Immunogenetics laboratory, Clermont-Ferrand University Hospital, Clermont-Ferrand, France
- EA7453 CHELTER, Clermont-Auvergne University, Clermont-Ferrand, France
| |
Collapse
|
13
|
Blandin L, Visentin J, Ralazamahaleo M, Lemal R, Rouzaire P. Characterization of the novel HLA-B*39:06:09 allele by sequencing-based typing. HLA 2024; 103:e15287. [PMID: 37942853 DOI: 10.1111/tan.15287] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/18/2023] [Revised: 10/23/2023] [Accepted: 10/27/2023] [Indexed: 11/10/2023]
Abstract
HLA-B*39:06:09 differs from HLA-B*39:06:02:01 by one nucleotide substitution in codon 135 in exon 3.
Collapse
Affiliation(s)
- Lucie Blandin
- Histocompatibility and Immunogenetics laboratory, Clermont-Ferrand University Hospital, Clermont-Ferrand, France
| | - Jonathan Visentin
- CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, Bordeaux, France
- Univ. Bordeaux, CNRS, ImmunoConcEpT, UMR 5164, 146 rue Léo Saignat, Bordeaux, France
| | - Mamy Ralazamahaleo
- CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, Bordeaux, France
| | - Richard Lemal
- Histocompatibility and Immunogenetics laboratory, Clermont-Ferrand University Hospital, Clermont-Ferrand, France
- EA7453 CHELTER, Clermont-Auvergne University, Clermont-Ferrand, France
| | - Paul Rouzaire
- Histocompatibility and Immunogenetics laboratory, Clermont-Ferrand University Hospital, Clermont-Ferrand, France
- EA7453 CHELTER, Clermont-Auvergne University, Clermont-Ferrand, France
| |
Collapse
|
14
|
Elsermans V, Visentin J, Top I, Pajot T, Labalette M. Characterization of the novel HLA-B*40:539 allele by sequencing-based typing. HLA 2024; 103:e15246. [PMID: 37789123 DOI: 10.1111/tan.15246] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2023] [Accepted: 09/24/2023] [Indexed: 10/05/2023]
Abstract
HLA-B*40:539 differs from HLA-B*40:01:01 by one nucleotide substitution in codon 46 in exon 2.
Collapse
Affiliation(s)
| | - Jonathan Visentin
- CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, Bordeaux, France
- Université de Bordeaux, UMR CNRS 5164 Immunoconcept, Bordeaux, France
| | - Isabelle Top
- CHU de Lille, Institut d'Immunologie-HLA, Lille, France
| | | | - Myriam Labalette
- CHU de Lille, Institut d'Immunologie-HLA, Lille, France
- Université de Lille, Inserm U1286 INFINITE, Lille, France
| |
Collapse
|
15
|
Cargou M, Elsermans V, Cambridge CA, Lasseaux E, Visentin J. Characterization of the novel HLA-DRB1*11:01:01:12N allele by sequencing-based typing. HLA 2023; 102:765-768. [PMID: 37605385 DOI: 10.1111/tan.15205] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2023] [Revised: 08/10/2023] [Accepted: 08/13/2023] [Indexed: 08/23/2023]
Abstract
HLA-DRB1*11:01:01:12N differs from HLA-DRB1*11:01:01:03 by one nucleotide substitution in intron 3 at position c.652+1G>C, hg19.
Collapse
Affiliation(s)
- Marine Cargou
- CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, Bordeaux, France
| | | | | | - Eulalie Lasseaux
- CHU de Bordeaux, Laboratoire de Génétique Médicale, Hôpital Pellegrin, Bordeaux, France
| | - Jonathan Visentin
- CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, Bordeaux, France
- Univ. Bordeaux, CNRS, ImmunoConcEpT, UMR 5164, Bordeaux, France
| |
Collapse
|
16
|
Chambord J, Chauveau B, Djabarouti S, Vignaud J, Taton B, Moreau K, Visentin J, Merville P, Xuereb F, Couzi L. Measurement of the Immunosuppressant Possession Ratio by Transplant Clinical Pharmacists Captures a Non-Adherence Associated With Antibody-Mediated Rejection. Transpl Int 2023; 36:11962. [PMID: 38089004 PMCID: PMC10713790 DOI: 10.3389/ti.2023.11962] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2023] [Accepted: 11/16/2023] [Indexed: 12/18/2023]
Abstract
Our objective was to calculate an immunosuppressant possession ratio (IPR) to diagnose non-adherence at the time of antibody-mediated rejection (ABMR). IPR was defined as the ratio of number of pills collected at the pharmacy to the number of pills prescribed over a defined period. In a first cohort of 91 kidney transplant recipients (KTRs), those with an IPR < 90% had more frequently a tacrolimus through level coefficient of variation >30% than patients with an IPR = 100% (66.7% vs. 29.4%, p = 0.05). In a case-control study, 26 KTRs with ABMR had lower 6 months IPRs than 26 controls (76% vs. 99%, p < 0.001). In KTRs with ABMR, non-adherence was more often diagnosed by a 6 months IPR < 90% than by clinical suspicion (73.1% vs 30.8%, p = 0.02). In the multivariable analysis, only de novo DSA and 6 months IPR < 90% were independently associated with ABMR, whereas clinical suspicion was not (odds ratio, 4.73; 95% CI, 1.17-21.88; p = 0.03; and odds ratio, 6.34; 95% CI, 1.73-25.59; p = 0.007, respectively). In summary, IPR < 90% is a quantifiable tool to measure immunosuppressant non-adherence. It is better associated with ABMR than clinical suspicion of non-adherence.
Collapse
Affiliation(s)
- Jérémy Chambord
- Service de Pharmacie, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France
| | - Bertrand Chauveau
- Service d’Anatomopathologie, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France
- CNRS-UMR 5164 ImmunoConcEpT, Université de Bordeaux, Bordeaux, France
| | - Sarah Djabarouti
- Service de Pharmacie, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France
- INSERM U1312 BRIEC, Université de Bordeaux, Bordeaux, France
| | - Jean Vignaud
- Service de Pharmacie, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France
| | - Benjamin Taton
- Service de Néphrologie, Transplantation, Dialyse, Aphérèse, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France
| | - Karine Moreau
- Service de Néphrologie, Transplantation, Dialyse, Aphérèse, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France
| | - Jonathan Visentin
- CNRS-UMR 5164 ImmunoConcEpT, Université de Bordeaux, Bordeaux, France
- Service d’Immunologie et Immunogénétique, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France
| | - Pierre Merville
- CNRS-UMR 5164 ImmunoConcEpT, Université de Bordeaux, Bordeaux, France
- Service de Néphrologie, Transplantation, Dialyse, Aphérèse, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France
| | - Fabien Xuereb
- Service de Pharmacie, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France
- INSERM U1034, Université de Bordeaux, Bordeaux, France
| | - Lionel Couzi
- CNRS-UMR 5164 ImmunoConcEpT, Université de Bordeaux, Bordeaux, France
- Service de Néphrologie, Transplantation, Dialyse, Aphérèse, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France
| |
Collapse
|
17
|
Laboux T, Lenain R, Visentin J, Flahaut G, Chamley P, Provôt F, Top I, Kerleau C, Labalette M, Choukroun G, Couzi L, Blancho G, Hazzan M, Maanaoui M. Impact of Preformed Donor-Specific Anti-HLA-Cw and Anti-HLA-DP Antibodies on Acute Antibody-Mediated Rejection in Kidney Transplantation. Transpl Int 2023; 36:11416. [PMID: 38076227 PMCID: PMC10698113 DOI: 10.3389/ti.2023.11416] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2023] [Accepted: 11/02/2023] [Indexed: 12/18/2023]
Abstract
Given the risk of rejection, the presence of preformed donor specific antibodies (DSA) contraindicates transplantation in most allocation systems. However, HLA-Cw and -DP DSA escape this censorship. We performed a multicentric observational study, in which the objective was to determinate risk factors of acute antibody-mediated rejection (aABMR) in recipients transplanted with preformed isolated Cw- or DP-DSA. Between 2010 and 2019, 183 patients were transplanted with a preformed isolated Cw- or DP-DSA (92 Cw-DSA; 91 DP-DSA). At 2 years, the incidence of aABMR was 12% in the Cw-DSA group, versus 28% in the DP-DSA group. Using multivariable Cox regression model, the presence of a preformed DP-DSA was associated with an increased risk of aABMR (HR = 2.32 [1.21-4.45 (p = 0.001)]) compared with Cw-DSA. We also observed a significant association between the DSA's MFI on the day of transplant and the risk of aABMR (HR = 1.09 [1.08-1.18], p = 0.032), whatever the DSA was. Interaction term analysis found an increased risk of aABMR in the DP-DSA group compared with Cw-DSA, but only for MFI below 3,000. These results may plead for taking these antibodies into account in the allocation algorithms, in the same way as other DSA.
Collapse
Affiliation(s)
- Timothée Laboux
- Department of Nephrology, Kidney Transplantation and Dialysis, CHU Lille, University of Lille, Lille, France
- INSERM U1167, RID-AGE, University of Lille, Lille, France
| | - Rémi Lenain
- Department of Nephrology, Kidney Transplantation and Dialysis, CHU Lille, University of Lille, Lille, France
- INSERM UMR 1246 – SPHERE, Nantes University, Tours University, Nantes, France
| | - Jonathan Visentin
- Department of Immunology and Immunogenetics, CHU Bordeaux, Bordeaux, France
- ImmunoConceEpT, CNRS UMR5164, Inserm ERL U1303, University of Bordeaux, Bordeaux, France
| | - Gauthier Flahaut
- Department of Nephrology, Internal Medicine, Dialysis and Transplantation, CHU Amiens, Jules Verne University of Picardie, Amiens, France
- EA7517, MP3CV Laboratory, Jules Verne University of Picardie, Amiens, France
| | - Paul Chamley
- Department of Nephrology, CH Roubaix, Roubaix, France
| | - François Provôt
- Department of Nephrology, Kidney Transplantation and Dialysis, CHU Lille, University of Lille, Lille, France
| | - Isabelle Top
- Department of Immunology-HLA, CHU Lille, University of Lille, Lille, France
| | - Clarisse Kerleau
- CHU Nantes, Service de Néphrologie-Immunologie Clinique, ITUN, Nantes, France
- Nantes Université, INSERM, Center for Research in Transplantation and Translational Immunology, UMR 1064, ITUN, Nantes, France
| | - Myriam Labalette
- Department of Immunology-HLA, CHU Lille, University of Lille, Lille, France
- INSERM UMR1286, INFINITE, University of Lille, Lille, France
| | - Gabriel Choukroun
- Department of Nephrology, Internal Medicine, Dialysis and Transplantation, CHU Amiens, Jules Verne University of Picardie, Amiens, France
- EA7517, MP3CV Laboratory, Jules Verne University of Picardie, Amiens, France
| | - Lionel Couzi
- ImmunoConceEpT, CNRS UMR5164, Inserm ERL U1303, University of Bordeaux, Bordeaux, France
- Department of Nephrology, Transplantation, Dialysis and Apheresis, CHU Bordeaux, Bordeaux, France
| | - Gilles Blancho
- CHU Nantes, Service de Néphrologie-Immunologie Clinique, ITUN, Nantes, France
- Nantes Université, INSERM, Center for Research in Transplantation and Translational Immunology, UMR 1064, ITUN, Nantes, France
| | - Marc Hazzan
- Department of Nephrology, Kidney Transplantation and Dialysis, CHU Lille, University of Lille, Lille, France
| | - Mehdi Maanaoui
- Department of Nephrology, Kidney Transplantation and Dialysis, CHU Lille, University of Lille, Lille, France
- INSERM U1190, EGID, Institut Pasteur Lille, CHU Lille, University of Lille, Lille, France
| |
Collapse
|
18
|
Cargou M, Andreani M, Galluccio T, Wojciechowski E, Visentin J. Characterization of the novel HLA-DPA1*01:159 allele by sequencing-based typing. HLA 2023; 102:647-648. [PMID: 37605369 DOI: 10.1111/tan.15200] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2023] [Accepted: 08/09/2023] [Indexed: 08/23/2023]
Abstract
HLA-DPA1*01:159 differs from HLA-DPA1*01:03:01:03 by one nucleotide substitution in codon 120 in exon 3.
Collapse
Affiliation(s)
- Marine Cargou
- CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, Bordeaux, France
| | - Marco Andreani
- Laboratorio d'Immunogenetica dei Trapianti, IRCCS Ospedale Pediatrico Bambino Gesù, Roma, Italy
| | - Tiziana Galluccio
- Laboratorio d'Immunogenetica dei Trapianti, IRCCS Ospedale Pediatrico Bambino Gesù, Roma, Italy
| | - Elodie Wojciechowski
- CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, Bordeaux, France
- Bordeaux University, CNRS, INSERM, ImmunoConcEpt, UMR 5164, ERL 1303, Bordeaux, France
| | - Jonathan Visentin
- CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, Bordeaux, France
- Bordeaux University, CNRS, INSERM, ImmunoConcEpt, UMR 5164, ERL 1303, Bordeaux, France
| |
Collapse
|
19
|
Cargou M, Andreani M, Battarra M, Tenchon O, Visentin J. Characterization of the novel HLA-DRB3*02:192 allele by sequencing-based typing. HLA 2023; 102:640-641. [PMID: 37604199 DOI: 10.1111/tan.15201] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2023] [Accepted: 08/09/2023] [Indexed: 08/23/2023]
Abstract
HLA-DRB3*02:192 differs from DRB3*02:02:01:02 by one nucleotide substitution in codon 204 in exon 4.
Collapse
Affiliation(s)
- Marine Cargou
- Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, CHU de Bordeaux, Bordeaux, France
| | - Marco Andreani
- Laboratorio d'Immunogenetica dei Trapianti, IRCCS Ospedale Pediatrico Bambino Gesù, Roma, Italy
| | - Mariarosa Battarra
- Laboratorio d'Immunogenetica dei Trapianti, IRCCS Ospedale Pediatrico Bambino Gesù, Roma, Italy
| | - Oceane Tenchon
- Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, CHU de Bordeaux, Bordeaux, France
| | - Jonathan Visentin
- Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, CHU de Bordeaux, Bordeaux, France
- CNRS, INSERM, ImmunoConcEpt, UMR 5164, ERL 1303, Bordeaux University, Bordeaux, France
| |
Collapse
|
20
|
Cargou M, Andreani M, Giustiniani P, Duclaut M, Visentin J. Characterization of the novel HLA-DPA1*01:150 allele by sequencing-based typing. HLA 2023; 102:543-545. [PMID: 37381637 DOI: 10.1111/tan.15144] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2023] [Accepted: 06/20/2023] [Indexed: 06/30/2023]
Abstract
HLA-DPA1*01:150 differs from HLA-DPA1*01:03:01:05 by one nucleotide substitution in codon 190 in exon 4.
Collapse
Affiliation(s)
- Marine Cargou
- CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, Bordeaux, France
| | - Marco Andreani
- Laboratorio d'Immunogenetica dei Trapianti, IRCCS Ospedale Pediatrico Bambino Gesù, Roma, Italy
| | - Paola Giustiniani
- Laboratorio d'Immunogenetica dei Trapianti, IRCCS Ospedale Pediatrico Bambino Gesù, Roma, Italy
| | - Marion Duclaut
- CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, Bordeaux, France
- Bordeaux University, CNRS, INSERM, ImmunoConcEpt, UMR 5164, ERL 1303, Bordeaux, France
| | - Jonathan Visentin
- CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, Bordeaux, France
- Bordeaux University, CNRS, INSERM, ImmunoConcEpt, UMR 5164, ERL 1303, Bordeaux, France
| |
Collapse
|
21
|
Cargou M, Elsermans V, Top I, Wojciechowski E, Visentin J. Characterization of the novel HLA-C*12:384 allele by sequencing-based typing. HLA 2023; 102:538-540. [PMID: 37370209 DOI: 10.1111/tan.15143] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2023] [Revised: 06/19/2023] [Accepted: 06/20/2023] [Indexed: 06/29/2023]
Abstract
HLA-C*12:384 differs from HLA-C*12:03:01:02 by one nucleotide substitution in codon 42 in exon 2.
Collapse
Affiliation(s)
- Marine Cargou
- CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, Bordeaux, France
| | | | - Isabelle Top
- Institut d'Immunologie-HLA, CHU de Lille, Lille, France
| | - Elodie Wojciechowski
- CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, Bordeaux, France
- CNRS, INSERM, ImmunoConcEpt, UMR 5164, ERL 1303, Bordeaux University, Bordeaux, France
| | - Jonathan Visentin
- CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, Bordeaux, France
- Institut d'Immunologie-HLA, CHU de Lille, Lille, France
| |
Collapse
|
22
|
Blandin L, Visentin J, Cargou M, Lemal R, Rouzaire P. Characterization of the novel HLA-DPA1*02:115 allele by sequencing-based typing. HLA 2023; 102:548-549. [PMID: 37496397 DOI: 10.1111/tan.15169] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2023] [Accepted: 07/18/2023] [Indexed: 07/28/2023]
Abstract
HLA-DPA1*02:115 differs from HLA-DPA1*02:01:01:06 by one nucleotide substitution in codon 224 in exon 4.
Collapse
Affiliation(s)
- Lucie Blandin
- Histocompatibility and Immunogenetics Laboratory, Clermont-Ferrand University Hospital, Clermont-Ferrand, France
| | - Jonathan Visentin
- CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, Bordeaux, France
- Univ. Bordeaux, CNRS, ImmunoConcEpT, UMR 5164, Bordeaux, France
| | - Marine Cargou
- CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, Bordeaux, France
- Univ. Bordeaux, CNRS, ImmunoConcEpT, UMR 5164, Bordeaux, France
| | - Richard Lemal
- Histocompatibility and Immunogenetics Laboratory, Clermont-Ferrand University Hospital, Clermont-Ferrand, France
- Clermont-Auvergne University, EA7453 CHELTER, Clermont-Ferrand, France
| | - Paul Rouzaire
- Histocompatibility and Immunogenetics Laboratory, Clermont-Ferrand University Hospital, Clermont-Ferrand, France
- Clermont-Auvergne University, EA7453 CHELTER, Clermont-Ferrand, France
| |
Collapse
|
23
|
Cargou M, Elsermans V, Top I, Ralazamahaleo M, Visentin J. Characterization of the novel HLA-B*51:370 allele by sequencing-based typing. HLA 2023; 102:84-86. [PMID: 36751704 DOI: 10.1111/tan.14991] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2023] [Accepted: 02/03/2023] [Indexed: 02/09/2023]
Abstract
HLA-B*51:370 differs from HLA-B*51:01:01:04 by one nucleotide substitution in codon 276 in exon 5.
Collapse
Affiliation(s)
- Marine Cargou
- CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, Bordeaux, France
| | | | - Isabelle Top
- CHU de Lille, Institut d'Immunologie-HLA, Lille, France
| | - Mamy Ralazamahaleo
- CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, Bordeaux, France
| | - Jonathan Visentin
- CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, Bordeaux, France
- Univ. Bordeaux, CNRS, ImmunoConcEpT, UMR 5164, Bordeaux, France
| |
Collapse
|
24
|
Cargou M, Elsermans V, Top I, Ralazamahaleo M, Visentin J. Characterization of the novel HLA-DPB1*1463:01N allele by sequencing-based typing. HLA 2023. [PMID: 37329309 DOI: 10.1111/tan.15133] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2023] [Revised: 06/02/2023] [Accepted: 06/06/2023] [Indexed: 06/19/2023]
Abstract
HLA-DPB1*1463:01N differs from HLA-DPB1*02:01:02:04 by one nucleotide substitution in codon 128 in exon 3.
Collapse
Affiliation(s)
- Marine Cargou
- Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, CHU de Bordeaux, Bordeaux, France
| | - Vincent Elsermans
- CHU de Lille, Institut d'Immunologie-HLA, Bd du Professeur Jules Leclercq, Lille, France
| | - Isabelle Top
- CHU de Lille, Institut d'Immunologie-HLA, Bd du Professeur Jules Leclercq, Lille, France
| | - Mamy Ralazamahaleo
- Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, CHU de Bordeaux, Bordeaux, France
| | - Jonathan Visentin
- Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, CHU de Bordeaux, Bordeaux, France
- Univ. Bordeaux, CNRS, ImmunoConcEpT, UMR 5164, Bordeaux, France
| |
Collapse
|
25
|
Cargou M, Elsermans V, Top I, Guidicelli G, Visentin J. Characterization of the novel HLA-B*44:324:02 allele by sequencing-based typing. HLA 2023. [PMID: 37322815 DOI: 10.1111/tan.15131] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2023] [Accepted: 06/02/2023] [Indexed: 06/17/2023]
Abstract
HLA-B*44:324:02 differs from HLA-B*44:324:01 by one nucleotide substitution in codon 99 in exon 3.
Collapse
Affiliation(s)
- Marine Cargou
- CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, Bordeaux, France
| | | | - Isabelle Top
- CHU de Lille, Institut d'Immunologie-HLA, Lille, France
| | - Gwendaline Guidicelli
- CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, Bordeaux, France
| | - Jonathan Visentin
- CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, Bordeaux, France
- Univ. Bordeaux, CNRS, ImmunoConcEpT, UMR 5164, Bordeaux, France
| |
Collapse
|
26
|
Blandin L, Visentin J, Cargou M, Rouzaire P, Lemal R. Characterization of the novel HLA-DQA1*01:64:02 allele by sequencing-based typing. HLA 2023. [PMID: 37204140 DOI: 10.1111/tan.15100] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2023] [Revised: 05/04/2023] [Accepted: 05/05/2023] [Indexed: 05/20/2023]
Abstract
HLA-DQA1*01:64:02 differs from HLA-DQA1*01:64:01 by one nucleotide substitution in codon 123 in exon 3.
Collapse
Affiliation(s)
- Lucie Blandin
- Histocompatibility and Immunogenetics Laboratory, Clermont-Ferrand University Hospital, Clermont-Ferrand, France
| | - Jonathan Visentin
- Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, Place Amélie Raba Léon, CHU de Bordeaux, Bordeaux, France
- CNRS, ImmunoConcEpT, UMR 5164, University of Bordeaux, Bordeaux, France
| | - Marine Cargou
- Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, Place Amélie Raba Léon, CHU de Bordeaux, Bordeaux, France
- CNRS, ImmunoConcEpT, UMR 5164, University of Bordeaux, Bordeaux, France
| | - Paul Rouzaire
- Histocompatibility and Immunogenetics Laboratory, Clermont-Ferrand University Hospital, Clermont-Ferrand, France
- EA(UR)7453 CHELTER, Clermont-Auvergne University, Clermont-Ferrand, France
| | - Richard Lemal
- Histocompatibility and Immunogenetics Laboratory, Clermont-Ferrand University Hospital, Clermont-Ferrand, France
- EA(UR)7453 CHELTER, Clermont-Auvergne University, Clermont-Ferrand, France
| |
Collapse
|
27
|
Poe JC, Fang J, Zhang D, Lee MR, DiCioccio RA, Su H, Qin X, Zhang JY, Visentin J, Bracken SJ, Ho VT, Wang KS, Rose JJ, Pavletic SZ, Hakim FT, Jia W, Suthers AN, Curry-Chisolm IM, Horwitz ME, Rizzieri DA, McManigle WC, Chao NJ, Cardones AR, Xie J, Owzar K, Sarantopoulos S. Single-cell landscape analysis unravels molecular programming of the human B cell compartment in chronic GVHD. JCI Insight 2023:169732. [PMID: 37129971 PMCID: PMC10393230 DOI: 10.1172/jci.insight.169732] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/03/2023] Open
Abstract
Alloreactivity can drive autoimmune syndromes. After allogeneic hematopoietic stem cell transplantation (allo-HCT) chronic graft-versus-host disease (cGVHD), a B cell-mediated autoimmune-like syndrome, commonly occurs. Because donor-derived B cells continually develop under selective pressure from host alloantigens, aberrant B Cell Receptor (BCR)-activation and IgG production can emerge and contribute to cGVHD pathobiology. To better understand molecular programing of B cells under selective pressure of alloantigens, we performed scRNA-Seq analysis on high numbers of purified B cells from allo-HCT patients. An unsupervised analysis revealed 10 clusters, distinguishable by signature genes for maturation, activation and memory. We found striking transcriptional differences in the memory B cell compartment after allo-HCT compared to healthy or infected individuals. To identify intrinsic properties when B-cell tolerance is lost after allo-HCT, we then assessed clusters for differentially expressed genes (DEGs) between patients with vs. without autoimmune-like manifestations (Active cGVHD vs. No cGVHD, respectively). DEGs were found in Active cGVHD in both naive and BCR-activated clusters, suggesting functional diversity. Some DEGs were also differentially expressed across most clusters, suggesting common molecular programs that may promote B cell plasticity. Our study of human allo-HCT and cGVHD provides new understanding of B-cell memory in the face of chronic alloantigen stimulation.
Collapse
Affiliation(s)
- Jonathan C Poe
- Department of Medicine, Division of Hematological Malignancies and Cellular, Duke University Medical Center, Durham, United States of America
| | - Jiyuan Fang
- Department of Biostatistics and Bioinformatics, Duke University Medical Center, Durham, United States of America
| | - Dadong Zhang
- Duke Cancer Institute, Duke University Medical Center, Durham, United States of America
| | - Marissa R Lee
- Department of Biostatistics and Bioinformatics, Duke University Medical Center, Durham, United States of America
| | - Rachel A DiCioccio
- Department of Medicine, Division of Hematological Malignancies and Cellular, Duke University Medical Center, Durham, United States of America
| | - Hsuan Su
- Department of Medicine, Division of Hematological Malignancies and Cellular, Duke University Medical Center, Durham, United States of America
| | - Xiaodi Qin
- Duke Cancer Institute, Duke University Medical Center, Durham, United States of America
| | - Jennifer Y Zhang
- Department of Dermatology, Duke University Medical Center, Durham, United States of America
| | - Jonathan Visentin
- Department of Medicine, Division of Hematological Malignancies and Cellular, Duke University Medical Center, Durham, United States of America
| | - Sonali J Bracken
- Department of Medicine, Division of Rheumatology and Immunology, Duke University Medical Center, Durham, United States of America
| | - Vincent T Ho
- Medical Oncology, Dana-Farber Cancer Institute, Boston, United States of America
| | - Kathy S Wang
- Medical Oncology, Dana-Farber Cancer Institute, Boston, United States of America
| | - Jeremy J Rose
- Experimental Transplantation and Immunology Branch, National Cancer Institute, Bethesda, United States of America
| | - Steven Z Pavletic
- Experimental Transplantation and Immunology Branch, National Cancer Institute, Bethesda, United States of America
| | - Frances T Hakim
- Experimental Transplantation and Immunology Branch, National Cancer Institute, Bethesda, United States of America
| | - Wei Jia
- Department of Medicine, Division of Hematological Malignancies and Cellular, Duke University Medical Center, Durham, United States of America
| | - Amy N Suthers
- Department of Medicine, Division of Hematological Malignancies and Cellular, Duke University Medical Center, Durham, United States of America
| | - Itaevia M Curry-Chisolm
- Department of Medicine, Division of Hematological Malignancies and Cellular, Duke University Medical Center, Durham, United States of America
| | - Mitchell E Horwitz
- Department of Medicine, Division of Hematological Malignancies and Cellular, Duke University Medical Center, Durham, United States of America
| | - David A Rizzieri
- Department of Medicine, Division of Hematological Malignancies and Cellular, Duke University Medical Center, Durham, United States of America
| | - William C McManigle
- Department of Medicine, Division of Hematological Malignancies and Cellular, Duke University Medical Center, Durham, United States of America
| | - Nelson J Chao
- Department of Medicine, Division of Hematological Malignancies and Cellular, Duke University Medical Center, Durham, United States of America
| | - Adela R Cardones
- Department of Dermatology, Duke University Medical Center, Durham, United States of America
| | - Jichun Xie
- Department of Biostatistics and Bioinformatics, Duke University Medical Center, Durham, United States of America
| | - Kouros Owzar
- Department of Biostatistics and Bioinformatics, Duke University Medical Center, Durham, United States of America
| | - Stefanie Sarantopoulos
- Department of Medicine, Division of Hematological Malignancies and Cellular, Duke University Medical Center, Durham, United States of America
| |
Collapse
|
28
|
Cargou M, Elsermans V, Top I, Wojciechowski E, Visentin J. Characterization of the novel HLA-A*24:587 allele by sequencing-based typing. HLA 2023. [PMID: 37067775 DOI: 10.1111/tan.15066] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2023] [Accepted: 04/06/2023] [Indexed: 04/18/2023]
Abstract
HLA-A*24:587 differs from HLA-A*24:02:01:01 by one nucleotide substitution in codon 220 in exon 4.
Collapse
Affiliation(s)
- Marine Cargou
- CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, Bordeaux, France
| | | | - Isabelle Top
- Institut d'Immunologie-HLA, CHU de Lille, Lille, France
| | - Elodie Wojciechowski
- CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, Bordeaux, France
- CNRS, Univ. Bordeaux, Bordeaux, France
| | - Jonathan Visentin
- CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, Bordeaux, France
- CNRS, Univ. Bordeaux, Bordeaux, France
| |
Collapse
|
29
|
Elsermans V, Visentin J, Top I, Pajot T, Labalette M. Characterization of the novel HLA-C*03:552 allele by sequencing-based typing. HLA 2023. [PMID: 37016809 DOI: 10.1111/tan.15056] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2023] [Revised: 03/27/2023] [Accepted: 03/28/2023] [Indexed: 04/06/2023]
Abstract
HLA-C*03:552 differs from HLA-C*03:04:01:01 by one nucleotide substitution in codon 72 in exon 2.
Collapse
Affiliation(s)
- Vincent Elsermans
- CHU de Lille, Institut d'Immunologie-HLA, Bd du Professeur Jules Leclercq, Lille, France
| | - Jonathan Visentin
- CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, Place Amélie Raba Léon, Bordeaux, France
- Université de Bordeaux, UMR CNRS 5164 Immunoconcept, 146 rue Léo Saignat, Bordeaux, France
| | - Isabelle Top
- CHU de Lille, Institut d'Immunologie-HLA, Bd du Professeur Jules Leclercq, Lille, France
| | - Thibault Pajot
- CHU de Lille, Institut d'Immunologie-HLA, Bd du Professeur Jules Leclercq, Lille, France
| | - Myriam Labalette
- CHU de Lille, Institut d'Immunologie-HLA, Bd du Professeur Jules Leclercq, Lille, France
- Université de Lille, Inserm U1286 INFINITE, Lille, France
| |
Collapse
|
30
|
Cargou M, Elsermans V, Top I, Ralazamahaleo M, Visentin J. Characterization of the novel HLA-DPB1*1348:01 allele by sequencing-based typing. HLA 2023; 101:313-314. [PMID: 36394166 PMCID: PMC10100256 DOI: 10.1111/tan.14885] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2022] [Accepted: 11/13/2022] [Indexed: 11/18/2022]
Abstract
HLA-DPB1*1348:01 differs from HLA-DPB1*14:01:01:01 by one nucleotide substitution in codon 147 in exon 3.
Collapse
Affiliation(s)
- Marine Cargou
- CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, Bordeaux, France
| | | | - Isabelle Top
- CHU de Lille, Institut d'Immunologie-HLA, Lille, France
| | - Mamy Ralazamahaleo
- CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, Bordeaux, France
| | - Jonathan Visentin
- CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, Bordeaux, France.,Université de Bordeaux, CNRS, Immuno Concept, Bordeaux, France
| |
Collapse
|
31
|
Cargou M, Elsermans V, Top I, Wojciechowski E, Visentin J. Characterization of the novel HLA-DPB1*11:01:06 allele by sequencing-based typing. HLA 2023; 101:311-312. [PMID: 36411507 PMCID: PMC10100016 DOI: 10.1111/tan.14899] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2022] [Accepted: 11/18/2022] [Indexed: 11/23/2022]
Abstract
HLA-DPB1*11:01:06 differs from HLA-DPB1*11:01:01:01 by one nucleotide substitution in codon 21 in exon 2.
Collapse
Affiliation(s)
- Marine Cargou
- CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, Bordeaux, France
| | - Vincent Elsermans
- CHU de Lille, Institut d'Immunologie-HLA, Bd du Professeur Jules Leclercq, Lille, France
| | - Isabelle Top
- CHU de Lille, Institut d'Immunologie-HLA, Bd du Professeur Jules Leclercq, Lille, France
| | - Elodie Wojciechowski
- CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, Bordeaux, France.,Univ. Bordeaux, CNRS, ImmunoConcEpT, UMR 5164, Bordeaux, France
| | - Jonathan Visentin
- CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, Bordeaux, France.,Univ. Bordeaux, CNRS, ImmunoConcEpT, UMR 5164, Bordeaux, France
| |
Collapse
|
32
|
Cargou M, Andreani M, Battarra M, Ralazamahaleo M, Visentin J. Characterization of the novel HLA-DQA1*05:05:14 allele by sequencing-based typing. HLA 2023; 101:299-300. [PMID: 36416663 PMCID: PMC10098539 DOI: 10.1111/tan.14902] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2022] [Revised: 11/18/2022] [Accepted: 11/21/2022] [Indexed: 11/24/2022]
Abstract
HLA-DQA1*05:05:14 differs from HLA-DQA1*05:05:01:04 by one nucleotide substitution in codon -8 in exon 1.
Collapse
Affiliation(s)
- Marine Cargou
- CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, Bordeaux, France
| | - Marco Andreani
- Laboratorio d'Immunogenetica dei Trapianti, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy
| | - Mariarosa Battarra
- Laboratorio d'Immunogenetica dei Trapianti, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy
| | - Mamy Ralazamahaleo
- CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, Bordeaux, France
| | - Jonathan Visentin
- CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, Bordeaux, France.,Univ. Bordeaux, CNRS, ImmunoConcEpT, UMR 5164, Bordeaux, France
| |
Collapse
|
33
|
Cargou M, Elsermans V, Top I, Wojciechowski E, Visentin J. Characterization of the novel HLA-B*08:302 allele by sequencing-based typing. HLA 2023; 101:278-280. [PMID: 36412840 PMCID: PMC10100224 DOI: 10.1111/tan.14898] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2022] [Accepted: 11/18/2022] [Indexed: 11/23/2022]
Abstract
HLA-B*08:302 differs from HLA-B*08:01:01:01 by one nucleotide substitution in codon 116 in exon 3.
Collapse
Affiliation(s)
- Marine Cargou
- CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, Bordeaux, France
| | - Vincent Elsermans
- CHU de Lille, Institut d'Immunologie-HLA, Bd du Professeur Jules Leclercq, Lille, France
| | - Isabelle Top
- CHU de Lille, Institut d'Immunologie-HLA, Bd du Professeur Jules Leclercq, Lille, France
| | - Elodie Wojciechowski
- CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, Bordeaux, France.,Univ. Bordeaux, CNRS, ImmunoConcEpT, UMR 5164, Bordeaux, France
| | - Jonathan Visentin
- CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, Bordeaux, France.,Univ. Bordeaux, CNRS, ImmunoConcEpT, UMR 5164, Bordeaux, France
| |
Collapse
|
34
|
Cargou M, Andreani M, Troiano M, Guidicelli G, Visentin J. Characterization of the novel HLA-DQA1*02:01:14 allele by sequencing-based typing. HLA 2023; 101:298-299. [PMID: 36403237 PMCID: PMC10099613 DOI: 10.1111/tan.14896] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2022] [Revised: 11/15/2022] [Accepted: 11/17/2022] [Indexed: 11/21/2022]
Abstract
HLA-DQA1*02:01:14 differs from HLA-DQA1*02:01:01:02 by one nucleotide substitution in codon 105 in exon 3.
Collapse
Affiliation(s)
- Marine Cargou
- CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, Bordeaux, France
| | - Marco Andreani
- Laboratorio d'Immunogenetica dei Trapianti, IRCCS Ospedale Pediatrico Bambino Gesù, Roma, Italy
| | - Maria Troiano
- Laboratorio d'Immunogenetica dei Trapianti, IRCCS Ospedale Pediatrico Bambino Gesù, Roma, Italy
| | - Gwendaline Guidicelli
- CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, Bordeaux, France
| | - Jonathan Visentin
- CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, Bordeaux, France.,CNRS, ImmunoConcEpT, Univ. Bordeaux, Bordeaux, France
| |
Collapse
|
35
|
Cargou M, Andreani M, Giustiniani P, Guidicelli G, Visentin J. Characterization of the novel HLA-DPA1*02:01:21 allele by sequencing-based typing. HLA 2023; 101:309-311. [PMID: 36401736 PMCID: PMC10099995 DOI: 10.1111/tan.14894] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2022] [Revised: 11/15/2022] [Accepted: 11/17/2022] [Indexed: 11/21/2022]
Abstract
HLA-DPA1*02:01:21 differs from HLA-DPA1*02:01:01:03 by one nucleotide substitution in codon 190 in exon 4.
Collapse
Affiliation(s)
- Marine Cargou
- CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, Place Amélie Raba Léon, Bordeaux, France
| | - Marco Andreani
- Laboratorio d'Immunogenetica dei Trapianti, IRCCS Ospedale Pediatrico Bambino Gesù, Roma, Italy
| | - Paola Giustiniani
- Laboratorio d'Immunogenetica dei Trapianti, IRCCS Ospedale Pediatrico Bambino Gesù, Roma, Italy
| | - Gwendaline Guidicelli
- CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, Place Amélie Raba Léon, Bordeaux, France
| | - Jonathan Visentin
- CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, Place Amélie Raba Léon, Bordeaux, France.,Univ. Bordeaux, CNRS, ImmunoConcEpT, Bordeaux, France
| |
Collapse
|
36
|
Cargou M, Elsermans V, Raclet V, Wojciechowski E, Visentin J. Characterization of the novel HLA-C*05:01:01:81Q allele by sequencing-based typing. HLA 2023. [PMID: 36841930 DOI: 10.1111/tan.15009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2023] [Revised: 02/22/2023] [Accepted: 02/23/2023] [Indexed: 02/27/2023]
Abstract
HLA-C*05:01:01:81Q differs from HLA-C*05:01:01:02 by one nucleotide substitution in position 202 in intron 1 (c.74-2A>G, hg19).
Collapse
Affiliation(s)
- Marine Cargou
- CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, Bordeaux, France
| | | | - Virginie Raclet
- CHU de Bordeaux, Laboratoire de Génétique Médicale, Hôpital Pellegrin, Bordeaux, France
| | - Elodie Wojciechowski
- CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, Bordeaux, France.,Univ. Bordeaux, CNRS, ImmunoConcEpT, UMR 5164, Bordeaux, France
| | - Jonathan Visentin
- CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, Bordeaux, France.,Univ. Bordeaux, CNRS, ImmunoConcEpT, UMR 5164, Bordeaux, France
| |
Collapse
|
37
|
Cargou M, Elsermans V, Top I, Wojciechowski E, Visentin J. Characterization of the novel HLA-A*24:585 allele by sequencing-based typing. HLA 2023. [PMID: 36754583 DOI: 10.1111/tan.14993] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2023] [Accepted: 02/03/2023] [Indexed: 02/10/2023]
Abstract
HLA-A*24:585 differs from HLA-A*24:02:01:01 by one nucleotide substitution in codon -15 in exon 1.
Collapse
Affiliation(s)
- Marine Cargou
- CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, Bordeaux, France
| | | | - Isabelle Top
- CHU de Lille, Institut d'Immunologie-HLA, Lille, France
| | - Elodie Wojciechowski
- CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, Bordeaux, France.,Univ. Bordeaux, CNRS, ImmunoConcEpT, UMR 5164, Bordeaux, France
| | - Jonathan Visentin
- CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, Bordeaux, France.,Univ. Bordeaux, CNRS, ImmunoConcEpT, UMR 5164, Bordeaux, France
| |
Collapse
|
38
|
Cargou M, Elsermans V, Top I, Guidicelli G, Visentin J. Characterization of the novel HLA-DRB1*01:140 allele by sequencing-based typing. HLA 2023. [PMID: 36754601 DOI: 10.1111/tan.14992] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2023] [Accepted: 02/03/2023] [Indexed: 02/10/2023]
Abstract
HLA-DRB1*01:140 differs from HLA-DRB1*01:02:01:01 by one nucleotide substitution in codon 147 in exon 3.
Collapse
Affiliation(s)
- Marine Cargou
- CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, Bordeaux, France
| | | | - Isabelle Top
- CHU de Lille, Institut d'Immunologie-HLA, Lille, France
| | - Gwendaline Guidicelli
- CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, Bordeaux, France
| | - Jonathan Visentin
- CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, Bordeaux, France.,Univ. Bordeaux, CNRS, ImmunoConcEpT, UMR 5164, Bordeaux, France
| |
Collapse
|
39
|
Basher F, Visentin J, Jia W, Poe JC, Su H, Sofian C, DiCioccio R, Curry-Chisolm I, Bracken S, Ho VT, Sisirak V, Horwitz ME, Chao NJ, Sarantopoulos S. The DNA Sensor AIM2 Promotes BCR-Activated B Cells in Chronic Graft-Versus-Host-Disease. Transplant Cell Ther 2023. [DOI: 10.1016/s2666-6367(23)00138-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
|
40
|
Acquier M, Taton B, Alain S, Garrigue I, Mary J, Pfirmann P, Visentin J, Hantz S, Merville P, Kaminski H, Couzi L. Cytomegalovirus DNAemia Requiring (Val)Ganciclovir Treatment for More Than 8 Weeks Is a Key Factor in the Development of Antiviral Drug Resistance. Open Forum Infect Dis 2023; 10:ofad018. [PMID: 36817745 PMCID: PMC9933945 DOI: 10.1093/ofid/ofad018] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2022] [Accepted: 01/19/2023] [Indexed: 01/25/2023] Open
Abstract
Background Prolonged (val)ganciclovir [(V)GCV] exposure for ≥6 weeks is a known predisposing factor for cytomegalovirus (CMV) drug resistance. However, the selection of this threshold was based on limited data. In this study, we sought to reappraise the risk factors for the development of (V)GCV resistance through a specific focus on kidney transplant recipients (KTRs). Methods This single-center retrospective study included 313 consecutive KTRs treated for a first CMV episode. Adjusted Cox multivariate regression analysis was used for identifying independent risk factors. Results Antiviral drug resistance was identified in 20 (6%) KTRs. A cumulative (V)GCV exposure for more than 6 weeks (regardless of the viral load) was not associated with antiviral drug resistance (hazard ratio [HR] = 2.45, 95% confidence interval [CI] = 0.33-18.30, P = .38). In contrast, persistent CMV DNAemia requiring (V)GCV treatment for more than 8 weeks was the main independent risk factor for antiviral drug resistance (HR = 11.68, 95% CI = 2.62-52.01, P = .001). The (V)GCV treatment for more than 8 weeks was given to 9% and 18% of patients who had persistent or recurrent CMV DNAemia, respectively. These scenarios were associated with the occurrence of drug resistance in 39% and 12% of cases, respectively. Conclusions Cumulative (V)GCV exposure ≥6 weeks regardless of the viral load is not associated with antiviral drug resistance. In contrast, prolonged exposure to (V)GCV during CMV replication (with a cutoff ³8 weeks) seems to be a key factor.
Collapse
Affiliation(s)
- M Acquier
- Department of Nephrology, Transplantation, Dialysis and Apheresis, Bordeaux University Hospital, Bordeaux, France
| | - B Taton
- Department of Nephrology, Transplantation, Dialysis and Apheresis, Bordeaux University Hospital, Bordeaux, France
| | - S Alain
- National Reference Center for Herpes Viruses, Virology Department, Limoges University Hospital, LimogesFrance.,UMR INSERM U1092, RESINFIT, Limoges University, LimogesFrance
| | - I Garrigue
- Laboratory of Virology, Bordeaux University Hospital, Bordeaux, France
| | - J Mary
- Department of Nephrology, Transplantation, Dialysis and Apheresis, Bordeaux University Hospital, Bordeaux, France
| | - P Pfirmann
- Department of Nephrology, Transplantation, Dialysis and Apheresis, Bordeaux University Hospital, Bordeaux, France
| | - J Visentin
- CNRS-UMR 5164 ImmunoConcEpT, Bordeaux University, Bordeaux, France.,Laboratory of Immunology and Immunogenetics, Bordeaux University Hospital, Bordeaux, France
| | - S Hantz
- National Reference Center for Herpes Viruses, Virology Department, Limoges University Hospital, LimogesFrance.,UMR INSERM U1092, RESINFIT, Limoges University, LimogesFrance
| | - P Merville
- Department of Nephrology, Transplantation, Dialysis and Apheresis, Bordeaux University Hospital, Bordeaux, France.,CNRS-UMR 5164 ImmunoConcEpT, Bordeaux University, Bordeaux, France
| | - H Kaminski
- Department of Nephrology, Transplantation, Dialysis and Apheresis, Bordeaux University Hospital, Bordeaux, France.,CNRS-UMR 5164 ImmunoConcEpT, Bordeaux University, Bordeaux, France
| | - L Couzi
- Department of Nephrology, Transplantation, Dialysis and Apheresis, Bordeaux University Hospital, Bordeaux, France.,CNRS-UMR 5164 ImmunoConcEpT, Bordeaux University, Bordeaux, France
| |
Collapse
|
41
|
Cargou M, Elsermans V, Top I, Blandin L, Visentin J. Characterization of the novel HLA-A*11:422 allele by sequencing-based typing. HLA 2022; 100:624-625. [PMID: 35924325 PMCID: PMC9804577 DOI: 10.1111/tan.14757] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/29/2022] [Accepted: 08/02/2022] [Indexed: 01/05/2023]
Abstract
HLA-A*11:422 differs from HLA-A*11:01:01:01 by one nucleotide substitution in codon 285 in exon 5.
Collapse
Affiliation(s)
- Marine Cargou
- CHU de Bordeaux, Laboratoire d'Immunologie et ImmunogénétiqueHôpital PellegrinBordeauxFrance
| | | | - Isabelle Top
- CHU de LilleInstitut d'Immunologie‐HLALilleFrance
| | - Lucie Blandin
- CHU de Bordeaux, Laboratoire d'Immunologie et ImmunogénétiqueHôpital PellegrinBordeauxFrance
| | - Jonathan Visentin
- CHU de Bordeaux, Laboratoire d'Immunologie et ImmunogénétiqueHôpital PellegrinBordeauxFrance,CNRS, ImmunoConcEpT, UMR 5164Univ. BordeauxBordeauxFrance
| |
Collapse
|
42
|
Cargou M, Elsermans V, Top I, Wojciechowski E, Visentin J. Characterization of the novel HLA-C*17:01:18 allele by sequencing-based typing. HLA 2022; 100:646-648. [PMID: 35920676 PMCID: PMC9804487 DOI: 10.1111/tan.14755] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/29/2022] [Accepted: 08/02/2022] [Indexed: 01/05/2023]
Abstract
HLA-C*17:01:18 differs from HLA-C*17:01:01:05 by one nucleotide substitution in codon 18 in exon 2.
Collapse
Affiliation(s)
- Marine Cargou
- CHU de Bordeaux, Laboratoire d'Immunologie et ImmunogénétiqueHôpital PellegrinBordeauxFrance
| | - Vincent Elsermans
- CHU de LilleInstitut d'Immunologie‐HLA, Bd du Professeur Jules LeclercqLilleFrance
| | - Isabelle Top
- CHU de LilleInstitut d'Immunologie‐HLA, Bd du Professeur Jules LeclercqLilleFrance
| | - Elodie Wojciechowski
- CHU de Bordeaux, Laboratoire d'Immunologie et ImmunogénétiqueHôpital PellegrinBordeauxFrance,Univ. Bordeaux, CNRS, ImmunoConcEpTBordeauxFrance
| | - Jonathan Visentin
- CHU de Bordeaux, Laboratoire d'Immunologie et ImmunogénétiqueHôpital PellegrinBordeauxFrance,Univ. Bordeaux, CNRS, ImmunoConcEpTBordeauxFrance
| |
Collapse
|
43
|
Cargou M, Andreani M, Galluccio T, Blandin L, Visentin J. Characterization of the novel HLA-DRB3*02:179N allele by sequencing-based typing. HLA 2022; 100:658-659. [PMID: 35922968 PMCID: PMC9804616 DOI: 10.1111/tan.14754] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/29/2022] [Accepted: 08/02/2022] [Indexed: 01/05/2023]
Abstract
HLA-DRB3*02:179N differs from DRB3*02:02:01:02 by one nucleotide substitution in codon 98 in exon 3.
Collapse
Affiliation(s)
- Marine Cargou
- Laboratoire d'Immunologie et ImmunogénétiqueCHU de BordeauxBordeauxFrance,University Bordeaux, CNRS, ImmunoConcEpTBordeauxFrance
| | - Marco Andreani
- Laboratorio d'Immunogenetica dei TrapiantiIRCCS Ospedale Pediatrico Bambino GesùRomaItaly
| | - Tiziana Galluccio
- Laboratorio d'Immunogenetica dei TrapiantiIRCCS Ospedale Pediatrico Bambino GesùRomaItaly
| | - Lucie Blandin
- Laboratoire d'Immunologie et ImmunogénétiqueCHU de BordeauxBordeauxFrance
| | - Jonathan Visentin
- Laboratoire d'Immunologie et ImmunogénétiqueCHU de BordeauxBordeauxFrance,University Bordeaux, CNRS, ImmunoConcEpTBordeauxFrance
| |
Collapse
|
44
|
Cargou M, Andreani M, Bianculli AG, Guidicelli G, Visentin J. Characterization of the novel HLA-DQA1*01:89 allele by sequencing-based typing. HLA 2022; 100:661-662. [PMID: 35925051 PMCID: PMC9804194 DOI: 10.1111/tan.14756] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/29/2022] [Accepted: 08/02/2022] [Indexed: 01/05/2023]
Abstract
HLA-DQA1*01:89 differs from HLA-DQA1*01:01:01:01 by one nucleotide substitution in codon -5 in exon 1.
Collapse
Affiliation(s)
- Marine Cargou
- CHU de Bordeaux, Laboratoire d'Immunologie et ImmunogénétiqueHôpital PellegrinBordeauxFrance
| | - Marco Andreani
- Laboratorio d'Immunogenetica dei TrapiantiIRCCS Ospedale Pediatrico Bambino GesùRomaItaly
| | | | - Gwendaline Guidicelli
- CHU de Bordeaux, Laboratoire d'Immunologie et ImmunogénétiqueHôpital PellegrinBordeauxFrance
| | - Jonathan Visentin
- CHU de Bordeaux, Laboratoire d'Immunologie et ImmunogénétiqueHôpital PellegrinBordeauxFrance,Univ. Bordeaux, CNRS, ImmunoConcEpTBordeauxFrance
| |
Collapse
|
45
|
Cargou M, Andreani M, Battarra M, Wojciechowski E, Visentin J. Characterization of the novel
HLA‐DPA1
*01:03:40
allele by sequencing‐based typing. HLA 2022; 100:403-404. [DOI: 10.1111/tan.14711] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2022] [Revised: 06/09/2022] [Accepted: 06/10/2022] [Indexed: 11/28/2022]
Affiliation(s)
- Marine Cargou
- CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique Hôpital Pellegrin, Place Amélie Raba Léon Bordeaux France
| | - Marco Andreani
- Laboratorio d'Immunogenetica dei Trapianti IRCCS Ospedale Pediatrico Bambino Gesù Rome Italy
| | - Mariarosa Battarra
- Laboratorio d'Immunogenetica dei Trapianti IRCCS Ospedale Pediatrico Bambino Gesù Rome Italy
| | - Elodie Wojciechowski
- CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique Hôpital Pellegrin, Place Amélie Raba Léon Bordeaux France
- CNRS, ImmunoConcEpT Univ. Bordeaux Bordeaux France
| | - Jonathan Visentin
- CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique Hôpital Pellegrin, Place Amélie Raba Léon Bordeaux France
- CNRS, ImmunoConcEpT Univ. Bordeaux Bordeaux France
| |
Collapse
|
46
|
Cargou M, Andreani M, Troiano M, Ralazamahaleo M, Visentin J. Characterization of the novel
HLA
‐
DQA1
*
05
:
53
allele by sequencing‐based typing. HLA 2022; 100:396-397. [DOI: 10.1111/tan.14705] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2022] [Accepted: 06/07/2022] [Indexed: 12/19/2022]
Affiliation(s)
- Marine Cargou
- CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique Hôpital Pellegrin, Place Amélie Raba Léon Bordeaux France
| | - Marco Andreani
- Laboratorio d'Immunogenetica dei Trapianti IRCCS Ospedale Pediatrico Bambino Gesù Roma Italy
| | - Maria Troiano
- Laboratorio d'Immunogenetica dei Trapianti IRCCS Ospedale Pediatrico Bambino Gesù Roma Italy
| | - Mamy Ralazamahaleo
- CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique Hôpital Pellegrin, Place Amélie Raba Léon Bordeaux France
| | - Jonathan Visentin
- CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique Hôpital Pellegrin, Place Amélie Raba Léon Bordeaux France
- University of Bordeaux CNRS, ImmunoConcEpT, UMR 5164 Bordeaux France
| |
Collapse
|
47
|
Cargou M, Elsermans V, Top I, Ralazamahaleo M, Visentin J. Characterization of the novel
HLA
‐
DQB1
*
02
:
200
allele by sequencing‐based typing. HLA 2022; 100:398-399. [DOI: 10.1111/tan.14706] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2022] [Accepted: 06/07/2022] [Indexed: 11/26/2022]
Affiliation(s)
- Marine Cargou
- CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique Hôpital Pellegrin, Place Amélie Raba Léon Bordeaux France
| | | | - Isabelle Top
- CHU de Lille Institut d'Immunologie‐HLA Lille France
| | - Mamy Ralazamahaleo
- CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique Hôpital Pellegrin, Place Amélie Raba Léon Bordeaux France
| | - Jonathan Visentin
- CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique Hôpital Pellegrin, Place Amélie Raba Léon Bordeaux France
- University of Bordeaux CNRS, ImmunoConcEpT, UMR 5164 Bordeaux France
| |
Collapse
|
48
|
Cargou M, Elsermans V, Top I, Ralazamahaleo M, Visentin J. Characterization of the novel
HLA
‐
DPB1
*
02
:
01
:
63
allele by sequencing‐based typing. HLA 2022; 100:406-408. [DOI: 10.1111/tan.14703] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2022] [Accepted: 06/07/2022] [Indexed: 11/29/2022]
Affiliation(s)
- Marine Cargou
- CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique Hôpital Pellegrin Bordeaux France
| | | | - Isabelle Top
- CHU de Lille Institut d'Immunologie‐HLA Lille France
| | - Mamy Ralazamahaleo
- CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique Hôpital Pellegrin Bordeaux France
| | - Jonathan Visentin
- CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique Hôpital Pellegrin Bordeaux France
- Univ. Bordeaux CNRS Bordeaux France
| |
Collapse
|
49
|
Chauveau B, Merville P, Soulabaille B, Taton B, Kaminski H, Visentin J, Vermorel A, Bouzgarrou M, Couzi L, Grenier N. Magnetic Resonance Elastography as Surrogate Marker of Interstitial Fibrosis in Kidney Transplantation: A Prospective Study. Kidney360 2022; 3:1924-1933. [PMID: 36514413 PMCID: PMC9717636 DOI: 10.34067/kid.0004282022] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/22/2022] [Accepted: 08/29/2022] [Indexed: 01/12/2023]
Abstract
Background Fibrosis progression is a major prognosis factor in kidney transplantation. Its assessment requires an allograft biopsy, which remains an invasive procedure at risk of complications. Methods We assessed renal stiffness by magnetic resonance elastography (MRE) as a surrogate marker of fibrosis in a prospective cohort of kidney transplant recipients compared with the histologic gold standard. Interstitial fibrosis was evaluated by three methods: the semi-quantitative Banff ci score, a visual quantitative evaluation by a pathologist, and a computer-assisted quantitative evaluation. MRE-derived stiffness was assessed at the superior, median, and inferior poles of the allograft. Results We initially enrolled 73 patients, but only 55 had measurements of their allograft stiffness by MRE before an allograft biopsy. There was no significant correlation between MRE-derived stiffness at the biopsy site and the ci score (ρ=-0.25, P=0.06) or with the two quantitative assessments (pathologist: ρ=-0.25, P=0.07; computer assisted: ρ=-0.21, P=0.12). We observed negative correlations between the stiffness of both the biopsy site and the whole allograft, with either the glomerulosclerosis percentage (ρ=-0.32, P=0.02 and ρ=-0.31, P=0.02, respectively) and the overall nephron fibrosis percentage, defined as the mean of the percentages of glomerulosclerosis and interstitial fibrosis (ρ=-0.30, P=0.02 and ρ=-0.28, P=0.04, respectively). At patient level, mean MRE-derived stiffness was similar across the three poles of the allograft (±0.25 kPa). However, a high variability of mean stiffness was found between patients, suggesting a strong influence of confounding factors. Finally, no significant correlation was found between mean MRE-derived stiffness and the slope of eGFR (P=0.08). Conclusions MRE-derived stiffness does not directly reflect the extent of fibrosis in kidney transplantation.
Collapse
Affiliation(s)
- Bertrand Chauveau
- CHU de Bordeaux, Service de Pathologie, Hôpital Pellegrin, Place Amélie Raba Léon, Bordeaux, France,Université de Bordeaux, CNRS, ImmunoConcEpT, UMR 5164, Bordeaux, France
| | - Pierre Merville
- Université de Bordeaux, CNRS, ImmunoConcEpT, UMR 5164, Bordeaux, France,CHU de Bordeaux, Service de Néphrologie, Transplantation Dialyse, Aphérèses, Hôpital Pellegrin, Bordeaux, France
| | - Bruno Soulabaille
- CHU de Bordeaux, Service d’Imagerie Diagnostique et Interventionnelle de l’Adulte, Hôpital Pellegrin, France
| | - Benjamin Taton
- CHU de Bordeaux, Service de Néphrologie, Transplantation Dialyse, Aphérèses, Hôpital Pellegrin, Bordeaux, France
| | - Hannah Kaminski
- Université de Bordeaux, CNRS, ImmunoConcEpT, UMR 5164, Bordeaux, France,CHU de Bordeaux, Service de Néphrologie, Transplantation Dialyse, Aphérèses, Hôpital Pellegrin, Bordeaux, France
| | - Jonathan Visentin
- Université de Bordeaux, CNRS, ImmunoConcEpT, UMR 5164, Bordeaux, France,CHU de Bordeaux, Laboratoire d’Immunologie et Immunogénétique, Hôpital Pellegrin, Bordeaux, France
| | - Agathe Vermorel
- CHU de Bordeaux, Service de Néphrologie, Transplantation Dialyse, Aphérèses, Hôpital Pellegrin, Bordeaux, France
| | - Mounir Bouzgarrou
- CHU de Bordeaux, Service d’Imagerie Diagnostique et Interventionnelle de l’Adulte, Hôpital Pellegrin, France
| | - Lionel Couzi
- Université de Bordeaux, CNRS, ImmunoConcEpT, UMR 5164, Bordeaux, France,CHU de Bordeaux, Service de Néphrologie, Transplantation Dialyse, Aphérèses, Hôpital Pellegrin, Bordeaux, France
| | - Nicolas Grenier
- CHU de Bordeaux, Service d’Imagerie Diagnostique et Interventionnelle de l’Adulte, Hôpital Pellegrin, France
| |
Collapse
|
50
|
Chauveau B, Merville P, Soulabaille B, Taton B, Kaminski H, Visentin J, Vermorel A, Bouzgarrou M, Couzi L, Grenier N. L’élastographie par résonance magnétique dans l’évaluation de la fibrose interstitielle en transplantation rénale : résultats d’une étude prospective. Nephrol Ther 2022. [DOI: 10.1016/j.nephro.2022.07.272] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|